title: Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
abstract: OBJECTIVE
  To assess the effect of gonadotropin-releasing hormone (GnRH) agonist treatment upon angiogenesis in uterine leiomyomata.
  
  
  METHODS
  Uterine leiomyomata specimens of 49 consecutive patients who underwent myomectomy or hysterectomy following presurgical treatment with (n = 23) and without (n = 26) GnRH agonist were stained immunohistochemically with antibody to factor VIII-related antigen. For each subject, age, parity, number of Lupron treatments, leiomyoma size (cm), and mean microvessel counts calculated from three fields (x400) were recorded. Differences in patient age, parity, microvessel counts and leiomyoma size between GnRH agonist treated and untreated patients were tested by unpaired Student's t test. Differences among the various number of doses were tested by one-way ANOVA, with Bonferonni and Neuman-Keuls post hoc tests between specific dose-number groups. The relationship between microvessel counts and leiomyoma size was tested by Pearson correlation test. Multivariate stepwise regression tested the relationship between the number of Lupron doses and microvessel counts, correcting for age, parity, and leiomyoma size. p < 0.05 was considered significant.
  
  
  RESULTS
  Patient age and parity were similar in GnRH treated and untreated patients (mean 43.3 +/- 6.6 versus 43.9 +/- 7.5 years and median 2 (range 0-7) versus 1 (range 0-5), p = 0.78 and p = 0.45, respectively). Microvessel counts of leiomyomata specimens treated presurgically with GnRH agonist therapy (median 22.7, range 6.7-65.7) were not significantly different from microvessel counts of specimens without presurgical GnRH agonist treatment (median 19.8, range 6-53; p = 0.77). No correlation between leiomyoma size and microvessel counts was noted (r = 0.06, P = 0.7).
  
  
  CONCLUSIONS
  Angiogenesis as assessed by microvessel counts in surgically removed leiomyomata is not affected by presurgical medical management with GnRH agonist therapy.
authors.affiliation: Department of Obstetrics and Gynecology, State University of New York at Brooklyn, NY 11203, USA. oabulafia@aol.com
authors.forename: O
authors.initials: O
authors.lastname: Abulafia
authors.forename: K
authors.initials: K
authors.lastname: Kleinhaus
authors.forename: G
authors.initials: G
authors.lastname: Levi
authors.forename: Y C
authors.initials: YC
authors.lastname: Lee
authors.forename: D M
authors.initials: DM
authors.lastname: Sherer
mesh_terms: D000704:Analysis of Variance; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000627:therapeutic use*; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry; D007889:Leiomyoma / Q000150:complications / Q000473:pathology* / Q000601:surgery; D016729:Leuprolide / Q000627:therapeutic use; D009389:Neovascularization, Pathologic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D016612:Paraffin Embedding; D011300:Preoperative Care; D012044:Regression Analysis; D014594:Uterine Neoplasms / Q000150:complications / Q000473:pathology* / Q000601:surgery; D014599:Uterus / Q000098:blood supply* / Q000187:drug effects / Q000601:surgery
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide